NCT00139230已完成2 期
TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 4
- 主要终点
- To evaluate the safety of a four day regimen of taxotere, cisplatin, 5-fluorouracil and high-dose leucovorin with growth factor support and ciprofloxacin.
研究概览
简要总结
The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.
详细描述
- Patients will be admitted to hospital and receive a one hour infusion of taxotere. Approximately 2 hours after taxotere is finished they will receive cisplatin, 5-fluorouracil, and leucovorin continuously over a 4 day period.
- Approximately 6-12 hours after the chemotherapy ends patients will be given growth factor support and ciprofloxacin until the patient's ANC level is greater than 10,000.
- Infusion of chemotherapy will be repeated every 28 days (1 cycle is 28 days).
- During each cycle patients will have blood tests performed weekly and may be asked to return to the Head and Neck Clinic for examination around the middle of each cycle.
- At the end of each cycle the impact of the chemotherapy will be assessed. If after 2 cycles, the cancer has not responded sufficiently the patient will not receive any more chemotherapy. However, if significant reduction in the size of the patients tumor is observed, a third and final cycle will be performed.
- During the fourth or fifth week of cycle 3, patients will undergo re-staging evaluation under anesthesia with primary-site biopsies and planning of radiotherapy.
- Within 2 weeks of completion of chemotherapy cycle 3 all patients will receive twice daily radiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic confirmation of squamous cell carcinoma of head and neck.
- •All patients with previously untreated Stage III or IV.
- •Measurable disease
- •Complete recovery from previous diagnostic or therapeutic procedures.
- •Life expectancy greater than 3 months
- •Creatinine less than or equal to 1.5
- •SGOT less than 1.5 x ULN
- •Alkaline phosphatase less than 2.5 x ULN
- •WBC greater than or equal to 4,000/mm
- •Platelet count greater than to equal to 100,000/mm
- •Hemoglobin greater than or equal to 10gm/dl
- •Patients of childbearing age must use effective contraception methods.
排除标准
- •Patients with previous head and neck cancer except those treated with surgery only.
- •Patients with concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- •Peripheral neuropathy exceeding grade
- •Cardiovascular or pulmonary disease
- •Pregnant or breastfeeding women
结局指标
主要结局
To evaluate the safety of a four day regimen of taxotere, cisplatin, 5-fluorouracil and high-dose leucovorin with growth factor support and ciprofloxacin.
次要结局
- To determine the efficacy of this regimen in patients with advances, previously untreated squamous cell carcinoma of the head and neck.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell CarcinomaStage III Oral Cavity Squamous Cell CarcinomaStage IVA Oral Cavity Squamous Cell CarcinomaNCT01542931Shanghai Jiao Tong University School of Medicine256
已完成
2 期
Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast CancerBreast NeoplasmsBreast CancerNCT00001239National Cancer Institute (NCI)100
进行中（未招募）
2 期
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaEpithelioid SarcomaCutaneous AngiosarcomaSarcomaNCT03069378Memorial Sloan Kettering Cancer Center41
Unknown
2 期
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04398056Sun Yat-sen University22
招募中
1 期
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaNCT06561152Stanford University20